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The increasing use of commercially available acellular dermis matrices for postmastectomy breast reconstruction seems to have
simplified the surgical procedure and enhanced the outcome. These materials, generally considered to be highly safe or with only
minor contraindications due to the necessary manipulation in preparatory phases, allow an easier one-phase surgical procedure,
in comparison with autologous flaps, offering a high patient satisfaction. Unfortunately, the claim for a higher rate of complications
associated with irradiation at the implant site, especially when the radiation therapy was given before the reconstructive surgery,
suggested a careful behaviour when this technique is preferred. However, this hypothesis was never submitted to a crucial test,
and data supporting it are often discordant or incomplete. To provide a comprehensive analysis of the field, we searched and
systematically reviewed papers published after year 2005 and registered clinical trials. On the basis of a meta-analysis of data, we
conclude that the negative effect of the radiotherapy on the breast reconstruction seems to be evident even in the case of acellular
dermis matrices aided surgery. However, more trials are needed to make solid conclusions and clarify the poor comprehension of
all the factors negatively influencing outcome.
1. Introduction
The acellular dermis matrices (ADM) are products derived
from the skin, deprived of their cellular component by
standardized treatments [1]. They provide a lower-lateral
coverage and support of the implants in the immediate
expander/implant-based breast reconstruction after mastec-
tomy. Additional main indications for their use are lack
of muscular coverage and cancer invasion to the pectoralis
major muscle, and skin nipple sparing mastectomy is a
relative indication [2].
The customized commercial products mainly differ in
their origin and in procedures for processing, storing, and
preparing them before usage. A recent paper compared
seven customized ADM suitable for the reconstruction of
the breast, in order to evaluate their cost/benefit ratios,
contraindications, and possible side effects [3].These authors
discuss main contraindications for the use of commercial
products, among others, namely, the presence of residues
of antibiotics or allergenic substances, the lack of sterility,
lower strength and elasticity, and higher cost. The Alloderm
(LifeCell Corporation, Branchburg, NJ, USA), a customized
derivative of the banked human skin, is the most widely
usedmaterial, despite a fewdisadvantages: longer rehydration
time, possible presence of antibiotics, and nonsterility of the
final product.
We analyzed the data reported in peer-reviewed papers,
in which irradiation at the site of ADM implant and its timing
are considered as possible interfering factors for surgical
outcome. The review includes an exhaustive description
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Table 1: Inclusion and exclusion criteria for quantitative meta-
analysis. Studies marked with asterisk were considered for qualita-
tive analysis.
Inclusion criteria
Primary data from prospective and retrospective observational
studies
Human studies
Studies that include data on prophylactic or therapeutic
mastectomy for cancer
Studies that stratify results on the basis of delivery of radiotherapy
before or after initiation of reconstruction
Studies based on single- or two-stage implant breast
reconstruction
Exclusion criteria
Experimental studies performed in laboratory animals or
“in vitro”
Review, surgical technique description, or case report; studies
with no relevant extractable outcomes∗
Studies focused solely on the elderly (>65 years)
Studies not published in English
Papers published before year 2005
of the procedure followed for recording and selecting the
published data, followed by their analysis and comment.
2. Materials and Methods
2.1. Search Strategy: Inclusion and Exclusion Criteria. The
electronic search was coordinated, according to the Boolean
syntax, in the following format: ((“acellular dermis” OR “acel-
lular dermal matrix” OR Alloderm OR Strattice OR allomax
OR Permacol OR Surgimed) AND (“breast reconstruction”
OR mammoplasty OR mammaplasty)). The names of two
commercial products (Flex-HD and DermaMatrix) gener-
ated ambiguity and therefore were omitted. The additional
terms ((radiation) OR irradiation) OR RXT, coordinated
with the previous terms by AND, restricted the search to
the main aim of this review. A manual refinement rejected
duplicate studies (those present in multiple databases), those
performed “in vitro” or in animals, and studies not reporting
original results or in which radiotherapy (RXT) was not
directly investigated. Only the most recently updated studies
were used.The reviews were carefully read, and other original
reports eventually not found by the electronic procedurewere
retrieved and considered.The inclusion and exclusion criteria
are reported in Table 1.
2.2. Databases. The bibliographic search was performed
(final updating: 21st February, 2014) at the PubMed (US
National Library of Medicine; http://www.ncbi.nlm.nih.gov/
pubmed) and at the Cochrane library (http://www.the
cochranelibrary.com/view/0/index.html). The completeness
of results was finally checked with a web-based tool, provided
by the library of our institution and searching in different
databases (Science Citation Index, Medline, Springer Link,
Walters Kluwer, Ovid, and Cross Ref).
We also considered the studies registered at the clinical
trials (USA, http://www.clinicaltrials.gov/) and at the
international clinical trials registry platform (World Health
Organisation, http://apps.who.int/trialsearch/Default.aspx)
(Table 2).
2.3. Data Collection and Analysis. Data collection included
the lead author, publication year, type of acellular dermal
matrix, time range of study, total number of patients, and total
number of reconstructions, with and without irradiation.
The total number and type of complications in each group
were recorded, as was the timing of RXT, before or after
the reconstruction.Chemotherapywas also considered,when
specified.The authors carefully followed the guidelines of the
meta-analysis of observational studies in epidemiology [5].
2.4. Statistics. We extracted data from the papers which
matched the inclusion criteria to evaluate the excessive risk
for complications due to the adjuvant RXT given at the site
of breast reconstruction. The forest and funnel plots of the
odds ratios with confidence intervals at 95% and log odds
ratios versus the standard error were built; the test of null
and heterogeneity were calculated under a fixed model. For
the necessary calculation we used the comprehensive meta-
analysis software version 2.2.064 (released July 27, 2011) [6].
3. Results
3.1. Selected Literature and Main Features. The algorithm for
the selection of the literaturematching the inclusion criteria is
explained in Figure 1.The limited number of studies retrieved
at the PubMed (𝑛 = 234 before the terms “radiation,” “radio-
therapy,” and “RXT” were included) represented no more
than 0.04% of all the papers describing different methods of
breast reconstruction, in relation with RXT, and present in
the same database under the period 2005–2014.This number
was reduced to 51when the terms ((radiation)OR irradiation)
OR RXT were added. The search at the Cochrane library
and at the institutional web-based tools gave 79 and 36
additional results, respectively. The 97 items remaining after
manual revision for duplicates included 29 papers lacking
extractable data but with relevant considerations or findings
and 17 registered clinical trials (Table 2), one of which with
published results [4]. Twenty works added results and were
included in the meta-analysis (Table 3). Thirty-two papers
(reviews and other publications without extractable data)
were excluded.
The level of evidence, according to the rating scale issued
by the American Society of Plastic Surgeons [27], was low;
80% of the selected papers scored 3 and the remaining 20%
scored 4.
The Alloderm is the most exploited and studied type
of ADM (Figure 2); studies on other commercially available
products are sporadic, frequently aimed to compare different
materials and procedures.
3.2. Meta-Analysis. We extracted the data for statistical anal-
ysis from twenty studies matching our inclusion criteria,
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157 records identified (42 at the
PubMed, 79 at the Cochrane library,
36 at the institutional tool)
93 records remained after duplicates removed and
were screened
77 full-text articles assessed for eligibility
60 studies included in qualitative synthesis and discussion
20 studies included in quantitative synthesis (meta-analysis)
17 additional records identified through other
sources (clinicaltrials.gov, international
clinical trials registry platform)
16 registered clinical trials without
results were summarized in table
17 full-text articles excluded (seven
experimental, four reply or discussion,
one case report in one subject older than
65 years, five focused on technical details
and/or cost)
Figure 1: The strategy followed for the selection of the literature. All papers were carefully matched with the inclusion/exclusion criteria.
Three search engines were used, for a total of 8 independent databases, as explained in the algorithm.
65%20%
5% 10%
Alloderm
Others
ND
Multiple
Figure 2:The use of different types of acellular dermismatrices in selected studies. Only the 60 papers included in the reviewwere considered.
The Alloderm (grey) was used in 65%, 20% used other acellular dermis matrices (fuchsia), 10% multiple ADM (pale blue), and 5% of authors
did not specify the type of ADM they used (yellow).
which reported the outcome of 3331 ADM-assisted recon-
structions. They were mainly retrospective cohort studies,
in which the observation period ranged between the years
2001 and 2012. With the exception of two works, performed
in UK [8] and Canada [7], one study reported the results
obtained in a private practice in USA [28] and the others
were done in departments of hospitals and universities in
the USA. Sixteen percent of reconstructions were irradiated
before, after, or before and after surgery; in these cases
the rate of development for complications was 33%. The
percentage of nonirradiated breasts which developed at least
one complication was instead lower (6%). The forest plot
(Figure 3) shows the odds ratios of each study; the black
diamond at the bottom represents the pooled effect. It fell
on the left of level 1 and does not cross it; this result means
that a significantly higher number of complications occurred
when the ADM-assisted breast reconstruction was combined
with RXT. In particular, eight studies found better results in
the absence of RXT and only one [21] disagreed. The test of
null was significant in both cases (𝑍 value = −8.841, 𝑃 value <
0.000); the complete results are shown in Tables 4 and 5. The
funnel plots (Figure 4) show an acceptable distribution of the
log odds ratio.
No more than 11 studies clearly specified the prevalence
of implant failure and the most frequent type of compli-
cations in the two groups with or without RXT, as shown
in Table 6, with higher prevalence of skin necrosis and
infection. The prevalence of capsular contracture, reported
in seven studies, was low (3%) but increased to 12% in
irradiated reconstructions. Others conditions, such as wound
dehiscence, haematoma, rippling, or implantmigration, were
not homogenously reported by all authors; therefore, we have
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Table 2: Studies registered at the clinical trials registry (http://www.clinicaltrials.gov/) of theUnited States of America and at the international
clinical trials registry platform (WorldHealthOrganisation, http://apps.who.int/trialsearch/) concerning the outcome ofADM-assisted breast
reconstruction after mastectomy.
NCT Status Location Expected NR Principal aim Radiotherapy
NCT 00616824 R USA 60 D versus B Exclusion criteria
NCT 00639106 NR USA 98 A versus B Exclusion criteria
NCT 00692692 NR USA 36 E versus D Not named
NCT 00872859 NR USA 196 A or D with/without RXT Principal condition
NCT 00956384 R Canada 144 C versus E Exclusion criteria
NCT 01027637 ND USA 30 Defining the stretch parameters of A Exclusion criteria
NCT 01222390 NR USA 30 F versus E Not named
NCT 01310075 R USA 398 A versus SM Exclusion criteria
NCT 01372917∗ NR USA 39 AM Exclusion criteria; sterilization with 𝛾-rays
NCT 01561287 R USA 40 A, neovascularisation Not named
NCT 01664091 NR USA 32 ADM versus others, with/without RXT Principal condition, postsurgery
NCT 01679223 NR USA 60 AM, incorporation Not named
NCT 1781299 R UK 50 A RTU versus SM Anamnestic record
NCT 01823107 R USA 25 G Exclusion criteria
NCT 01853436 R Italy 60 S Exclusion criteria
NCT 01959867 NR USA SM versus B Principal condition, prior to surgery
ISRCTN 67956295 NR UK 40 S versus SM Not named
A: alloderm; ADM: acellular dermal matrix; AM: allomax; B: traditional reconstruction; C: 1-stage dermal matrix/implant procedure; D: DermaMatrix; E:
2-stage tissue expander/implant procedure; F: ContourProfile© expander; G: Meso BioMatrix Acellular Peritoneum Matrix; ISCTNR: international standard
randomised controlled trial number register; NCT: national clinical trial accession number; R: recruiting; NR: not recruiting; RTU: ready to use; RXT: radiation
therapy; S: Strattice; SM: Surgimed; UK: United Kingdom; USA: United States of America. ∗Published results [4].
Study name Model Odds ratio and 95% Cl
0.1 0.2 0.5 1 2 5 10
Fixed
Joanna Nguyen et al., 2011
Gamboa-Bobadilla, 2006
Bindingnavele et al., 2007
Nahabedian, 2009
Namnoun, 2009
Colwell et al., 2011
Israeli and Feingold, 2011
Rawlani et al., 2011
Nicolau et al., 2012
Salzberg et al., 2011
Salzberg et al., 2013
Spear et al., 2012
Seth et al., 2012
Parks et al., 2012
Clemens and Kronowitz, 2012
Hanna et al., 2013
Patel et al., 2013
Potter et al., 2013
Weichman et al., 2013
Cheng and Saint-Cyr, 2012 
Figure 3: Forest plot of 20 studies. The authors reported the complications occurring in ADM-assisted immediate implant breast
reconstruction, with or without radiotherapy (RXT). Odds ratios and confidence intervals at 95% are plotted. The black diamond at the
bottom is the pooled odds ratio and its CI 95%. It completely falls to the left of 1.0 (<1), meaning that RXT significantly increases the risk of
complications.
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Figure 4: Funnel plots of 20 studies. Complications in ADM-assisted immediate implant breast reconstruction with or without RXT,
occurring with statistically significant difference. (B) Skin necrosis; (D) capsular contracture; (E) other complications, sparsely described;
(F) failure.
grouped them. The RXT significantly enhanced the risk for
skin necrosis and capsular contracture, as well as the implant
failure due to different conditions.
4. Discussion
The RXT as adjuvant therapy for patients affected by mam-
mary cancer is a trouble for the plastic surgeons as it
could cause a tissue insult possibly affecting the final out-
come of postmastectomy breast reconstruction.The relatively
recent introduction of ADM-assisted implant reconstruction
seemed to help a better procedure; however, its safety when
RXT is needed is still under debate and experimental data
are scanty and not conclusive. In many cases, as in the
majority of clinical trials more recently registered at the USA
repository, a history of previous irradiation is sufficient to
exclude the use of the ADM and prefer an autologous recon-
struction instead. In general, the authors of meta-analyses
and traditional reviews agreed that the RXT enhances the
risk of complications; however, no general agreement was
reached, nor all works were conclusive in this aspect. A recent
survey evaluated that at least 25% of patients submitted to
postmastectomy breast reconstruction, independently from
the use of ADM, and received prereconstruction RXT. The
prevalence was large, exceeding 50%, in those which received
postmastectomy RXT [29]. The relatively low rate of RXT
(16% of all reconstructions considered) in this work could
eventually reflect a bias in the choice of the technique, entail-
ing that the autologous reconstruction could be preferred to
the use of the ADM when the RXT was performed before
surgery or expected to be needed later. While the first case
could be confirmed at least in part by the general attitude of
considering previous irradiation as an exclusion criteria for
the use of expensive ADM (see Table 2), the second remains
largely hypothetical.
The rational of these warnings resides in the nature of
the ADM. They are generally protein derivatives, mainly
composed of collagen, to which elastin, proteoglycans, and
glycosaminoglycans may be added.The impact with ionizing
radiation to sterilize the dried form of Alloderm affected the
3D structure of the collagen matrix, and different species of
free radicals developed [28, 30, 31]. An unsolved issue is how
Plastic Surgery International 7
Table 4: Statistics under a fixed model for each study included in the meta-analysis.
Study name Odds ratio Lower limit Upper limit 𝑍 value 𝑃 value Relative weight Std. residual
Gamboa-Bobadilla, 2006 [9] 0.486 0.018 12.929 −0.431 0.667 0.55 −1.09
Bindingnavele et al. 2007 [10] 2.750 0.256 29.561 0.835 0.404 1.06 −0.08
Nahabedian, 2009 [11] 4.030 1.336 12.159 2.473 1.338 4.89 0.53
Namnoum, 2009 [12] 2.429 0.082 72.046 0.513 0.608 0.52 −0.12
Colwell et al. 2011 [13] 2.654 1.327 5.304 2.761 0.006 12.44 −0.38
Israeli and Feingold, 2011 [14] 1.268 0.474 3.391 0.474 0.636 6.17 −1.78
Joanna Nguyen et al. 2011 [15] 0.253 0.029 2.221 −1.240 0.215 1.27 −2.25
Rawlani et al. 2011 [16] 2.803 1.013 7.757 1.985 0.047 5.76 −0.14
Nicolau et al. 2012 [7] 0.342 0.018 6.468 −0.716 0.474 0.69 −1.46
Salzberg et al. 2011 [17] 2.890 0.791 10.555 1.605 0.108 3.56 −0.06
Salzberg et al. 2013 [18] 0.733 0.038 14.044 −0.206 0.837 0.68 −0.94
Spear et al. 2012 [19] 9.114 5.778 14.377 9.503 0.000 28.74 5.64
Seth et al. 2012 [20] 1.896 0.878 4.094 1.628 0.103 10.07 −1.24
Parks et al. 2012 [21] 0.426 0.191 0.948 −2.091 0.036 9.32 −5.03
Cheng et al. 2013 [22] 29.000 0.780 1077.623 1.826 0.068 0.46 1.23
Clemens and Kronowitz, 2012 [23] 4.126 1.929 8.822 3.655 0.000 10.33 0.86
Hanna et al. 2013 [24] 0.217 0.022 2.131 −1.311 0.190 1.14 −2.27
Patel et al. 2013 [25] 0.231 0.009 6.107 −1.877 0.380 0.56 −1.54
Potter et al. 2013 [8] 36.000 3.453 375.309 2.996 0.003 1.09 2.09
Weichman et al. 2013 [26] 21.364 1.139 400.534 2.047 0.041 0.69 1.31
Model: fixed 3.010 2.358 3.844 8.841 0.000
Table 5: Statistical evaluation of the results of meta-analysis. The test of null was performed for both the fixed and random models and was
significant. The heterogeneity and Tau-squared tests applied to the fixed model are also shown.
Model Test of null (2-tail) Heterogeneity Tau-squared
𝑍 value 𝑃 value 𝑄 value df (𝑄) 𝑃 value 𝐼-squared Tau-squared SE Variance Tau
Fixed −8.841 0.000 75.243 19 0.000 74.748 1.015 0.603 0.364 1.008
the modalities of irradiation could be modified to reduce the
impact on the skin and on the implant. In addition to the tim-
ing, which remains a possible additional risk factor (that was,
however, not supported by the experimental evidence), the
hypofractionation of the total dose of radiation (40Gy in 15
fractions over 3weeks)was associatedwith a higher incidence
of severe capsular contracture. A clinical study with similar
aim describes the changes of the native capsule architecture
in ADM- and non-ADM-assisted reconstructions, before and
after RXT [32]. In the presence of ADM and before RXT,
the amount of elastin fibers was roughly duplicated and the
number ofmacrophages fivefold reduced. However, when the
ADM was used, irradiation did not induce relevant changes
in the native capsule, not even excessive neovascularisation.
The authors used Alloderm, Strattice, and NeoForm. This
work did not report the modalities of irradiation, not even
the incidence of complications in no ADM-assisted recon-
structions. In 27 reconstructions with ADM, nine capsular
contracture (grade III-IV) and nine different complications
developed after irradiation. Nine complications exited in
implant failure. No capsular contraction nor failure, and only
three complications developed in the absence of irradiation.
The results of the meta-analysis presented in this review,
in which three previously not reported results have been
included [7, 8, 26], supported the thesis that the RXT
represents a serious challenge; the influence of its timing
in relation with surgery is, however, not noticeable due to
the scarcity of data. The general opinion that RXT is a risk
for higher rate of complications is, however, a controversial
issue. Only few authors of original works lacking extractable
data unequivocally concluded that RXT enhanced risk of
complications [33–38]. Unfortunately, the only study in the
field classified at level 1 of evidence only named RXT among
the exclusion criteria [39]. Ibrahim et al., 2013 [40], recently
found in a large database (19100 patients identified) the only
association of greater risk for postoperative urinary tract
infection in the group receiving the ADM and RXT. The
authors admitted that unconventional results could be due to
a bias derived from the very large number of cases in their
analysis. To this, it could be added as an emerging opinion
that in the context of greater morbidity due to the additional
insult of RXT, the use of ADM seems to be protective and
reduces the rate of complications, in particular capsular
contracture [41–43]. While a large number of researchers
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Table 6: Rate of complications by group (no RXT versus RXT).
Complication Number of studies No RXT (%) ES RXT (%) ES 𝑃 value
Overall 11 15.63 3.59 24.71 5.67 0.000
Infection 10 8.19 2.73 12.04 4.01 0.400
Skin necrosis 10 4.04 1.35 15.50 1.05 0.000
Seroma 9 3.61 1.20 4.60 1.53 0.045
Capsular contracture 6 2.88 1.09 11.90 4.50 0.033
Others 10 4.02 1.34 8.18 2.73 0.000
Failure 11 4.06 1.23 14.05 4.23 0.000
prefer to behave cautiously, as documented by the strategy
adopted by the majority of protocols deposited at the clinical
trials (Table 2); this suggestion was accepted in some reviews
[42, 43] and recently included in the guidelines of the
Association of Breast Surgery and the British Association
of Plastic, Reconstructive, and Aesthetic Surgeons [44]. This
document recognized that the RXT negatively affected the
outcome but suggested that the use of ADM could potentially
reduce the severity of capsular contracture.
In addition to capsular contracture, infection and implant
failure seemed to occur more frequently in irradiated breasts
[33]. Data we analysed here confirm this trend for all types
of complications and reached the statistical significance in
the case of skin necrosis and capsular contracture. The
most severe outcome, implant failure, was also significantly
enhanced, independently from the causes.
Several biases occur in the analysis. The influence of
chemotherapy, in relation with the concomitant need for
radiation therapy, was sporadically reported in details in the
reviewed papers, as were other recognized risk factors, such
as obesity, diabetes, smoking, and breast size [45–47]. The
data retrieved from the analysis of the literature did not
permit to stratify the observations in relation to the RXT; it
is specified by some authors that the risk factors were evenly
distributed among groups. Another source of perplexity
could rise from the consideration that, for its relatively
elevated cost [48], the use of ADM could be addressed to
patients with a lower risk for complications, or with a more
favourable stage of the cancer.This factor, poorly investigated
until now [2, 38], could put the suggested protective effect
under a more relative point of view.
5. Conclusions
Radiotherapy is generally considered a concomitant factor
negatively influencing the dynamics of breast reconstruction,
even when ADM is added. This fact, claimed by many
studies published on this argument, seems to emerge from
the meta-analysis presented here. The real impact of RXT
on the success of breast reconstruction techniques must be
better defined by studies falling in the level of evidence I
or II, namely, protocols specifically designed to define the
importance of the radiotherapy and planned as randomized,
single-, or multicenter studies of adequate quality. Better
assessment of anthropometric and behavioural conditions,
morbidity, and stage of the cancer in the two groups, with or
without RXT, should be added for clarity.
A better definition of histological evolution of the ADM
after surgery in sites that were previously irradiated should
also be of interest and even more in those undergoing RXT
after the surgery, particularly in terms of formation of oxygen
reactive species and radicals and collagen integrity.
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